Literature DB >> 16639067

A new graduated dosing regimen for phosphorus replacement in patients receiving nutrition support.

Kaleb A Brown1, Roland N Dickerson, Laurie M Morgan, Kathryn H Alexander, Gayle Minard, Rex O Brown.   

Abstract

BACKGROUND: Hypophosphatemia is a common metabolic complication in patients receiving specialized nutrition support. We changed our previously reported dosing algorithm because the low dose no longer appeared to be effective at increasing serum phosphorus concentrations. The purpose of this study was to evaluate the safety and efficacy of a revised weight-based phosphorus-dosing algorithm in critically ill trauma patients receiving specialized nutrition support.
METHODS: Seventy-nine adult trauma patients with hypophosphatemia (serum phosphorus concentration < or = 0.96 mmol/L) receiving nutrition support received an IV dose of phosphorus on day 1 according to the serum concentration of phosphorus: 0.73-0.96 mmol/L (0.32 mmol/kg, low dose), 0.51-0.72 mmol/L (0.64 mmol/kg, moderate dose), and < or = 0.5 mmol/L (1 mmol/kg, high dose). The IV phosphorus bolus dose was administered at 7.5 mmol/hour. Generally, patients with a serum potassium concentration <4 mmol/L received potassium phosphate and patients with a serum potassium concentration > or = 4 mmol/L received sodium phosphate. Patients who still had hypophosphatemia on day 2 were dosed using the new dosing algorithm by the nutrition support service according to that day's serum concentration of phosphorus, or empirically by the trauma service.
RESULTS: Of the 79 patients studied, 57 were male and 22 were female with a mean age of 44.8 +/- 20.6 years. Mean Injury Severity Scores and APACHE-II scores were 27.1 +/- 11.6 and 15.2 +/- 6.8, respectively. There was no difference in baseline characteristics among the 3 dosing groups. Of the 79 patients, 34 received the low dose, 30 received the moderate dose, and 15 received the high dose of phosphorous. Mean serum phosphorous concentrations on day 2 were significantly increased in the moderate-dosed group (0.64 +/- 0.06 to 0.77 +/- 0.22 mmol/L, p < .05) and high-dosed group (0.38 +/- 0.06 to 0.93 +/- 0.32 mmol/L, p < .01), respectively, when compared with day 1. Mean serum phosphorus concentrations were normal in all 3 groups on day 3. Serum concentrations of magnesium, sodium, and potassium, as well as arterial pH, were stable across the study. Mean concentrations of ionized calcium were not significantly different in any of the 3 dosing groups across the study period.
CONCLUSIONS: This weight-based phosphorus-dosing algorithm is safe for use in critically ill patients receiving nutrition support. The moderate and severe-dose regimens effectively increase serum phosphorus concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16639067     DOI: 10.1177/0148607106030003209

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  4 in total

Review 1.  Malnutrition and refeeding syndrome prevention in head and neck cancer patients: from theory to clinical application.

Authors:  Akil Kaderbay; Ihab Atallah; Eric Fontaine; Marine Chobert-Bakouline; Stephanie Schmitt; Philipp Mitariu; Christian Adrien Righini
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-22       Impact factor: 2.503

Review 2.  Treatment of hypophosphatemia in the intensive care unit: a review.

Authors:  Daniël A Geerse; Alexander J Bindels; Michael A Kuiper; Arnout N Roos; Peter E Spronk; Marcus J Schultz
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

3.  Hypophosphatemia at Admission is Associated with Increased Mortality in COVID-19 Patients.

Authors:  Ruoran Wang; Min He; Yan Kang
Journal:  Int J Gen Med       Date:  2021-09-07

4.  Augmented Renal Clearance Following Traumatic Injury in Critically Ill Patients Requiring Nutrition Therapy.

Authors:  Roland N Dickerson; Christin N Crawford; Melissa K Tsiu; Cara E Bujanowski; Edward T Van Matre; Joseph M Swanson; Dina M Filiberto; Gayle Minard
Journal:  Nutrients       Date:  2021-05-15       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.